[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"takayasu-arteritis-tak\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:takayasu-arteritis-tak":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,38,68,98,136,157,183],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100636891","monitoring-disease-activity-in-patients-with-takayasu-arteritis-with-the-omeract-takayasu-ultrasound-score-otus-100636891",false,"NCT07571577","Monitoring Disease Activity in Patients With Takayasu Arteritis With the OMERACT Takayasu Ultrasound Score (OTUS)","A Multicenter Prospective Observational Study on the Role of the OMERACT Takayasu Ultrasound Score (OTUS) in Monitoring Disease Activity in Patients With Takayasu Arteritis","MOTUS","Inclusion Criteria:\n\n* Age ≥18 years\n* Male and female\n* Diagnosis of TAK according to the 1990 ACR and\u002For 2022 ACR\u002FEULAR classification criteria\n* Active disease, defined as the presence of at least two of the following three domains:\n\n  * Clinical domain: new onset or worsening of clinical signs and\u002For symptoms attributable to TAK;\n  * Laboratory domain: elevation of inflammatory markers, defined as ESR and\u002For CRP above the upper limit of normal according to local laboratory standards, not attributable to causes other than TAK;\n  * Imaging domain: imaging evidence of active vasculitis on modalities other than ultrasound, including FDG-PET, magnetic resonance angiography (MRA), or computed tomography angiography (CTA).\n* Ability to undergo serial vascular ultrasound assessments during follow-up\n* Provision of signed informed consent\n\nExclusion Criteria:\n\n* Inability or contraindication to undergo vascular US\n* Severe comorbidities limiting participation or follow-up\n* Concomitant conditions that may confound ultrasound findings (e.g., significant atherosclerosis requiring intervention, complete occlusion of one of the arterial segments under investigation)\n* Diagnosis of another rheumatologic disease\n* Refusal or inability to provide informed consent","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","This is a multicenter prospective observational study aimed at evaluating the role of an ultrasonographic score in monitoring disease activity in patients with Takayasu arteritis (TAK). Patients with active disease, either at new diagnosis or during relapse, will undergo serial vascular US assessments during follow-up according to routine clinical practice at each participating centers. For each patient, an OMERACT-derived US score (OTUS) will be calculated. This score was developed and preliminarily validated in previous phases of a multistep project endorsed by OMERACT (Outcome Measures in Rheumatology), an international initiative focused on the development and validation of outcome measures in rheumatology. The study hypothesis is that this score is sensitive to change over time and can be used to monitor disease activity and predict outcome in patients with TAK.",[25],"Takayasu Arteritis (TAK)","NOT_YET_RECRUITING","2026-05-06",{"date":29,"type":30},"2026-05-11","ACTUAL",{"date":32,"type":21},"2026-07-01",{"date":34,"type":21},"2032-12-31",{"name":36,"class":37},"IRCCS San Raffaele","OTHER",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":46,"targetDuration":48,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100635876","global-initiative-on-takayasu-arteritis-gita-100635876","NCT07558382","Global Initiative on Takayasu Arteritis (GITA)","Takayasu's Arteritis Global Registry","GITA","Inclusion Criteria:\n\n* Each patient must fullfill the ACR 1990 or ACR\u002FEULAR 2021 criteria for Takayasu arteritis.\n* Patients (or legally acceptable representatives of subjects enrolled) have to\n* provide informed and free agreement to participate in the study and to disclose any medical event to the investigator. The parents or legally acceptable representative and the adolescent subject must be willing and able to comply with the study protocol requirements for the duration of the study\n* freely sign written and dated informed consent after being duly informed of the nature, significance, and implications of the study;\n* be informed that the patient enrolled may withdraw consent at any time without prejudice to future medical care.\n\nExclusion Criteria:\n\nPatients must be excluded from the study when the following criteria are observed:\n\n* The patient does not full-fill the ACR 1990 or ACR\u002FEULAR 2021 criteria for Takayasu arteritis\n* informed consent\u002Fassent is not provided and signed",{"count":47,"type":21},1000,"10 Years","Takayasu's Arteritis Global Registry aims to bring a large group of patients from different parts of the world to analyse and compare the patients' demographic, clinical, laboratory, radiological and prognostic features with outcomes, approaches to diagnosis, assessment, management and therapeutic interventions in different centers. The present project provides for both a retrospective and a prospective longitudinal study. The study is designed as retrospective for patients already diagnosed with TAK and treated with available treatments. Also, the study is designed as prospective for patients diagnosed with TAK after the initiation of the Registry or the adhesion to the project. This is thought as a multicentre, international study addressed to all Centers that will want to contribute to the present project. The study is non-interventional: demographic, clinical and therapeutic data required over time are collected with the routine diagnostic, clinical and therapeutic procedures usually carried out for the optimal management of patients and according with good clinical practice.",[25,51],"Takayasu's Arteritis",[53,54,55,56],"Takayasu's arteritis","prognosis","Registry","follow-up","RECRUITING","2026-04-23",{"date":60,"type":30},"2026-04-30",{"date":62,"type":30},"2025-08-05",{"date":64,"type":21},"2035-08",{"name":66,"class":37},"Marmara University",2,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100627671","phase-4-efficacy-and-safety-of-vunakizumab-and-ivarmacitinib-in-the-treatment-of-active-takayasus-arteritis-100627671","NCT07451665","Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis","A Prospective, Open-label, Controlled, Multiple Centers Clinical Study of the Efficacy and Safety for Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis (TAK): The VIVA-TAK Ttrial","VIVA-TAK","Inclusion Criteria:\n\n* a. Adult patients (aged between 18-70 years) fulfilling the 2022 ACR\u002FEULAR classification criteria for TAK with new-onset or relapsing disease.\n* b. Presence of active disease despite treatment with gluccorticoids combined with a conventional synthetic or biologic immunosuppressive agent other than JAK inhibitors and IL-17 inhibitors, including new-onset patients and relapsed patients.\n\nPatient is considered to have active disease by the investigator is the patients meets at least two of the following three criteria: i) one or more clinical manifestations determined by the investigator to be due to active TAK; ii) one or more findings on imaging of progressive disease; or iii) elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Clinical criteria included constitutional symptoms (fever, fatigue, and weight loss), musculoskeletal symptoms, vascular pain, neurological or visual symptoms, abdominal pain or angina, new or worsening limb claudication, loss of pulses, and worsening hypertension. Imaging criteria includes new vascular stenosis or aneurysms detected by ultrasound, computed tomography angiography (CTA), or magnetic resonance angiography.\n\nExclusion Criteria:\n\n* Participants are excluded from the study if any of the following criteria apply:\n\n  1. Medical Conditions\n\n     1. Severe disease from TAK for which urgent treatment with interventional vascular procedures or bypass surgery is considered necessary\n     2. Critical organ involvement of TAK, such as myocardial or coronary artery involvement, or cerebral ischemia, that is anticipated to need treatment during the study\n     3. Active hepatitis B or C virus infection\n     4. Active tuberculosis (Patients with latent tuberculosis infection could be enrolled with preventive therapy for tuberculosis flare)\n     5. Malignancy in the past 5 years (with the exception of fully excised non-melanoma skin cancer or cervical carcinoma in situ)\n     6. Poorly controlled diabetes\n     7. Patients with history of venous thrombosis\n     8. Upper GI bleeding within 3 months prior to enrollment\n     9. Uncontrolled heart failure\n     10. Refractory hypertension\n  2. Abnormal Laboratory Test Findings k. Serum liver enzyme elevation 3 times higher than the upper limits of normal range l. Severe renal function impairment with estimated glomerular filtration rate ≤ 30 ml\u002Fminute\u002F1.73 m2, calculated using the Modification of Diet in Renal Disease equation (doi:10.1056\u002FNEJMoa2102953)\n  3. Other Exclusion Criteria m. Females who are pregnant or intend to be pregnant during the time frame of the study n. History of treatment with JAKi or IL-17i. o. Any other medical, psychiatric, and\u002For social reason as determined by the investigator to be a contraindication for study participation","70 Years",{"count":78,"type":21},180,"INTERVENTIONAL",[81],"PHASE4","This is a prospective, open-label, controlled, multiple centers, randonmized clinical trial. It compares the clinical efficacy and safety of vunakizumab ivarmacitinib and glucocorticoids in the treatment of active Takayasu's arteritis.",[25],[85,86,87],"Vunakizumab","Ivarmacitinib","randomized controlled trial","2026-02-28",{"date":90,"type":30},"2026-03-05",{"date":92,"type":21},"2026-04-01",{"date":94,"type":21},"2029-03-31",{"name":96,"class":37},"Chinese SLE Treatment And Research Group",20,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":106,"minAge":18,"maxAge":107,"enrollmentInfo":108,"targetDuration":109,"studyType":22,"phases":4,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100254637","vasculitis-pregnancy-registry-100254637","NCT02593565","Vasculitis Pregnancy Registry","The Vasculitis Pregnancy Registry (V-PREG)","V-PREG","Inclusion Criteria:\n\n1. Women 18 years of age or older with one of the following diseases may take part in the study:\n\n   * Behçet's disease;\n   * Central nervous system (CNS) vasculitis;\n   * Cryoglobulinemic vasculitis (Cryoglobulinemia);\n   * Eosinophilic granulomatosis with polyangiitis (also called Churg-Strauss Syndrome);\n   * Giant Cell (Temporal) Arteritis (GCA);\n   * Granulomatosis with polyangiitis (also called Wegener's);\n   * IgA vasculitis (Henoch-Schoenlein purpura);\n   * Microscopic polyangiitis (MPA);\n   * Polyarteritis nodosa (PAN);\n   * Takayasu's arteritis (TAK);\n   * Urticarial vasculitis;\n   * Other\u002FSuspected Diagnosis.\n2. Women must be pregnant (self-report) at the time of enrollment into the registry.\n\nExclusion Criteria:\n\n1. Non-English speaking, with the exception of people who speak Spanish, Portuguese, Italian, or Turkish.\n2. Unable to provide consent.","FEMALE","50 Years",{"count":20,"type":21},"12 Months","The purpose of this study is to learn about the experience of women with vasculitis who become pregnant. In particular, the study will consist of several online surveys to assess\n\n1. each woman's vasculitis severity and pregnancy-related experiences, and\n2. pregnancy outcomes.",[112,113,114,115,116,117,118,119,120,121,122,123,25,124,125],"Vasculitis","Behcet's Disease","CNS Vasculitis","Cryoglobulinemic Vasculitis","Eosinophilic Granulomatosis With Polyangiitis (EGPA)","Churg-Strauss Syndrome (CSS)","Granulomatosis With Polyangiitis (GPA)","Wegener's Granulomatosis","IgA Vasculitis","Henoch-Schoenlein Purpura (HSP)","Microscopic Polyangiitis (MPA)","Polyarteritis Nodosa (PAN)","Urticarial Vasculitis","Systemic Vasculitis","2026-01-21",{"date":128,"type":30},"2026-01-23",{"date":130,"type":4},"2015-11",{"date":132,"type":21},"2027-12",{"name":134,"class":37},"University of Pennsylvania",1,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":135},"100619961","investigating-management-perspectives-and-attitudes-towards-care-in-takayasu-arteritis-100619961","NCT07351422","Investigating Management, Perspectives and Attitudes Towards Care in Takayasu Arteritis","TAK-IMPACT","Inclusion Criteria:\n\nFor the patient questionnaire:\n\n* Age ≥ 18 years\n* A formal diagnosis of TAK\n\nFor the physician questionnaire\n\n• A physician involved in the management\u002Fdecision-making for patients diagnosed with TAK\n\nExclusion Criteria:\n\nFor the patient questionnaire:\n\n* Age \\\u003C 18 years\n* Lack of a formal diagnosis of TAK\n* Patients without mental capacity or willingness to provide informed consent\n* Not UK based\n\nFor the physician questionnaire\n\n* Not involved in the management\u002F decision making for patients diagnosed with TAK\n* Not willing to take part\n* Not UK based",{"count":144,"type":21},50,"This study aims to understand the experiences of patients with Takayasu arteritis (TAK) and how physicians manage the condition. To achieve this, two separate questionnaires will be conducted: one for patients and one for physicians.",[147,25],"Takayasu Arteritis","2026-01-09",{"date":150,"type":30},"2026-01-20",{"date":152,"type":30},"2025-10-01",{"date":154,"type":21},"2027-03-15",{"name":156,"class":37},"University of Edinburgh",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":79,"phases":165,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":135},"100594007","phase-4-the-efficacy-and-safety-of-deucravacitinib-in-takayasus-arteritis-100594007","NCT07013838","The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis","Comparison of Deucravacitinib and Adalimumab for the Treatment of Relapsed Takayasu's Arteritis: The TYK-TAK Trial","Inclusion Criteria:\n\n* Participants are eligible to be included in the study only if all of the following criteria apply:\n\n  1. Signed Written Informed Consent\n\n     1. Participants fully understand the purpose, nature, method, and possible adverse reactions of the study, willing to consent to the trial and follow study protocol and sign informed consent.\n     2. Participants must have signed an Institutional Review Board (IRB)\u002FIndependent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines. This ICF must be obtained before performing any protocol related procedures that are not part of normal patient care.\n  2. Type of Participant and Target Disease Characteristics\n\n     1. Adult patients (aged 18 or older) fulfilling the 2022 ACR\u002FEULAR classification criteria for TAK.\n     2. Persistence of active disease or relapse despite treatment with GCs combined with a conventional synthetic or biologics immunosuppressive agent other than TNFi.\n     3. Active vasculitis by reader interpretation of FDG-PET at enrollment (by the same reader).\n  3. Reproductive Status The investigator or designee shall counsel women of childbearing potential (WOCBP) and male participants who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy.\n\nWOCBP must have a negative highly sensitive specify: urine or serum as required by local regulations pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotropin) within 24 hours prior to the start of study intervention.\n\nA female is eligible to participate if she is not pregnant or breastfeeding and at least 1 of the following conditions applies:\n\nIs not a WOCBP OR Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \\\u003C 1% per year) during the intervention period and for at least 5 half-lives after product administration and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction for the same period.\n\nWOCBP and male participants who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception.\n\nExclusion Criteria:\n\n* Participants are excluded from the study if any of the following criteria apply:\n\n  1. Medical Conditions\n\n     1. Severe disease from TAK for which urgent treatment with interventional procedures or bypass surgery is considered necessary\n     2. Critical organ involvement of TAK, such as myocardial or coronary artery involvement, or cerebral ischemia\n     3. Active hepatitis B or C virus infection, active tuberculosis infection\n     4. Malignancy in the past 5 years (with the exception of fully excised non-melanoma skin cancer or cervical carcinoma in situ)\n  2. Physical and Laboratory Test Findings\n\n     1. Serum liver enzyme tests 3 times higher than the upper limits of normal range\n     2. Estimated glomerular filtration rate ≤ 30 ml\u002Fminute\n  3. Other Exclusion Criteria\n\n     1. Females who are pregnant\n     2. Ever treated with TNFi (including adalimumab) and discontinued due to inadequate response or intolerance.\n     3. Any other sound medical, psychiatric, and\u002For social reason as determined by the investigator",{"count":144,"type":21},[81],"This is a 24-week, single-center, randomized, open-label trial conducted by Peking Union Medical College Hospital. The aim of this study is to assess the efficacy and safety of deucravacitinib in adult patients with relapsing TAK in comparison to patients treated with TNF inhibitor (TNFi), the most well-recognized therapeutic choice of non-glucocorticoid immunosuppressive for patients with relapsed or refractory TAK.",[25],[169,170,171,172,173,174],"Deucravacitinib","Adalimumab","Relapsed","Efficacy","Safety","Takayasu arteritis","2025-06-06",{"date":177,"type":30},"2025-06-10",{"date":179,"type":21},"2025-06-15",{"date":181,"type":21},"2028-03-31",{"name":96,"class":37},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":135},"100574997","a-registry-study-assessing-pro-dosing-patterns-and-safety-of-vunakizumab-in-patients-with-general-rheumatic-diseases-100574997","NCT06766552","A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.","A Multicenter Registry Study Assessing Patient Reported Outcome, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.","V-MIRACLE","Inclusion Criteria:\n\n1. Diagnosed with rheumatic autoimmune diseases such as ankylosing spondylitis\u002Fradiologically negative axial spondyloarthritis\u002Fpsoriatic arthritis\u002Fpolymyalgia rheumatica\u002FTakayasu arteritis\u002Fgiant cell arteritis\u002F non-ocular Behcet's disease\u002F enthesitis-related arthritis;\n2. Currently receiving or planning to receive fulvezinib treatment;\n3. Can follow up according to the doctor's advice;\n4. Able to understand and sign the informed consent form, understand the purpose of this study, and voluntarily participate in this study.\n\nExclusion Criteria:\n\n1.Investigator believes will prevent the subject from following and completing the study protocol",{"count":192,"type":21},10000,"Ankylosing spondylitis, radiographically negative axial spondyloarthritis, psoriatic arthritis, polymyalgia rheumatica, Takayasu arteritis, giant cell arteritis, non-ocular Behcet's disease, and enthesitis-related arthritis are common diseases in rheumatology. Traditional anti-rheumatic drugs are less effective and have greater side effects than biological agents. At present, there has been no large-scale registration study on rheumatic autoimmune diseases such as spondyloarthritis in China. However, data such as patient characteristics, medication patterns, and patient outcome reports of different rheumatology diseases can often serve as a reference for rheumatology clinicians to reasonably select treatment methods for different patients. Therefore, a large-scale registration study is needed to fill the gap in multi-disease registration studies in rheumatology departments in China.",[195,196,197,198,25,199,200,201],"Ankylosing Spondylitis (AS)","Psoriatic Arthritis (PsA)","Nr-axSpA","Polymyalgia Rheumatica (PMR)","Giant Cell Arteritis (GCA)","Behcet's Disease","Enthesitis-related Arthritis","2025-01-08",{"date":204,"type":30},"2025-01-09",{"date":206,"type":21},"2025-01-30",{"date":208,"type":21},"2030-06-30",{"name":210,"class":37},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]